NeonMind Biosciences Inc (TSE:LCR)
:LCR
Want to see TSE:LCR full AI Analyst Report?
LCR Stock Chart & Stats
C$0.04
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.04
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.03 - C$0.08
Previous CloseN/A
Volume126.00K
Average Volume (3M)290.69K
Market Cap
C$3.70M
Enterprise ValueC$3.34M
Total Cash (Recent Filing)C$206.03K
Total Debt (Recent Filing)C$1.14M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding92,499,870
10 Day Avg. Volume583,757
30 Day Avg. Volume290,695
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)-9.40
Price to Sales (P/S)0.00
P/FCF Ratio-6.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused R&D On Psilocybin TherapiesA clear, specialized R&D focus on psilocybin-based mental health treatments establishes a durable strategic direction. Specialization supports the development of proprietary drug candidates, targeted clinical programs and potential IP/licensing pathways, creating a repeatable route to commercial partnerships if trials succeed.
Improving Cash Flow TrendAn improvement in free cash flow versus 2024 signals operational progress that can materially extend runway if sustained. Reduced cash burn lowers near-term financing pressure, giving management more time to advance clinical milestones before raising additional capital or entering dilutive financings.
Moderate Absolute Debt LevelsRelatively modest absolute debt reduces immediate leverage burden compared with many biotech peers. Lower interest and repayment pressure preserves cash for R&D, maintains financial flexibility, and provides a cleaner capital structure to negotiate partnerships or licensing deals without heavy debt constraints.
Bears Say
No Meaningful RevenueThe absence of recurring revenue across multiple years means the company remains pre-commercial and dependent on external funding. Long-term sustainability hinges on successful clinical outcomes or licensing; until then, there is no proven commercial model to generate operating cash flow or validate market demand.
Persistent Operating And Net LossesOngoing operating and net losses steadily deplete capital and necessitate repeated fundraising. Continued losses limit the company's ability to self-fund clinical development, raise dilution risk for shareholders, and force management to allocate attention to financing rather than long-term product commercialization strategies.
Negative Shareholders' EquityNegative shareholders’ equity reflects cumulative deficits that weaken solvency and financial resilience. This condition restricts borrowing capacity, can increase cost of capital, and constrains strategic options—making the firm more reliant on dilutive equity or partnership deals to fund ongoing clinical programs.
NeonMind Biosciences Inc News
LCR FAQ
What was NeonMind Biosciences Inc’s price range in the past 12 months?
NeonMind Biosciences Inc lowest stock price was C$0.03 and its highest was C$0.08 in the past 12 months.
What is NeonMind Biosciences Inc’s market cap?
NeonMind Biosciences Inc’s market cap is C$3.70M.
When is NeonMind Biosciences Inc’s upcoming earnings report date?
NeonMind Biosciences Inc’s upcoming earnings report date is Aug 05, 2026 which is in 75 days.
How were NeonMind Biosciences Inc’s earnings last quarter?
NeonMind Biosciences Inc released its earnings results on Mar 03, 2026. The company reported -C$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.003.
Is NeonMind Biosciences Inc overvalued?
According to Wall Street analysts NeonMind Biosciences Inc’s price is currently Overvalued.
Does NeonMind Biosciences Inc pay dividends?
NeonMind Biosciences Inc does not currently pay dividends.
What is NeonMind Biosciences Inc’s EPS estimate?
NeonMind Biosciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NeonMind Biosciences Inc have?
NeonMind Biosciences Inc has 92,499,870 shares outstanding.
What happened to NeonMind Biosciences Inc’s price movement after its last earnings report?
NeonMind Biosciences Inc reported an EPS of -C$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of NeonMind Biosciences Inc?
Currently, no hedge funds are holding shares in TSE:LCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NeonMind Biosciences Inc
Lancaster Resources Inc. engages in the acquisition, exploration, and development of mineral properties and renewable energy projects. It has option to acquire a 100% interest in the Alkali Flat lithium brine project situated in Lordsburg, New Mexico, the United States. The company is based in West Vancouver, Canada.
Technical Analysis
Options Prices
Currently, No data available
---